Description. Umeclidinium/vilanterol (Anoro Ellipta) is a combination product containing a long-acting Anoro Ellipta Prescribing Information. Research
Anoro Ellipta is recommended if the patient experiences further exacerbations. Further information can be found in the Prescribing and Cost Guidance
by DA Hussar 2024 Cited by 1Consult a pharmacist or the package insert for information on drug safety Anoro Ellipta. Prescribing information. http:// www.gsksource.com/anoro
Avoid coadministration of ANORO with other anticholinergic-containing drugs as this may lead to an increase in anticholinergic adverse effects. Please see full Prescribing Information, including Patient Information, for ANORO.
Full US Prescribing Information, including BOXED WARNING and ANORO ELLIPTA, VI monotherapy and MABA (GSK ), developed in
Prescription Medicine. Anoro Ellipta is used for long-term regular For more information see Anoro Ellipta Consumer Medicine Information at www
ELLIPTA safely and effectively. See full prescribing information for ANORO ELLIPTA. ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder), for oral inhalation use Initial U.S. Approval: 2024 . INDICATIONS AND USAGE - ANORO ELLIPTA is a combination of umeclidinium, an anticholinergic, and . vilanterol, a long-acting beta
information of the prescribing provider, the signature of the ANORO ELLIPT AER 62.5-25 57. ANUCORT-HC.
ANORO. ELLIPTA safely and effectively. See full prescribing information for ANORO ELLIPTA. ANORO ELLIPTA (umeclidinium and vilanterol inhalation powder), for oral inhalation Initial U.S. Approval: 2024 . WARNING: ASTHMA-RELATED DEATH . See full prescribing information for complete boxed warning.
Comments